Potential Therapeutic Competition in Community-Living Older Adults in the U.S.: Use of Medications That May Adversely Affect a Coexisting Condition
Open accessThe DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: The 75% of older adults with multiple chronic conditions are at risk of therapeutic competition (i.e. treatment for one condition may adversely affect a coexisting condition). The objective was to determine the prevalence of potential therapeutic competition in community-living older adults. METHODS: Cross-sectional descriptive study of a representative sample of 5,815 community-living adults 65 and older in the U.S, enrolled 2007-2009. The 14 most common chronic conditions treated with at least one medication were ascertained from Medicare claims. Medication classes recommended in national disease guidelines for these conditions and used by ≥ 2% of participants were identified from in-person interviews conducted 2008-2010. Criteria for potential therapeutic competition included: 1), well-acknowledged adverse medication effect; 2) mention in disease guidelines; or 3) report in a systematic review or two studies published since 2000. Outcomes included prevalence of situations of potential therapeutic competition and frequency of use of the medication in individuals with and without the competing condition. RESULTS: Of 27 medication classes, 15 (55.5%) recommended for one study condition may adversely affect other study conditions. Among 91 possible pairs of study chronic conditions, 25 (27.5%) have at least one potential therapeutic competition. Among participants, 1,313 (22.6%) received at least one medication that may worsen a coexisting condition; 753 (13%) had multiple pairs of such competing conditions. For example, among 846 participants with hypertension and COPD, 16.2% used a nonselective beta-blocker. In only 6 of 37 cases (16.2%) of potential therapeutic competition were those with the competing condition less likely to receive the medication than those without the competing condition. CONCLUSIONS: One fifth of older Americans receive medications that may adversely affect coexisting conditions. Determining clinical outcomes in these situations is a research and clinical priority. Effects on coexisting conditions should be considered when prescribing medications.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Barnett, K., Mercer, S. W., Norbury, M., Watt, G., Wyke, S., & Guthrie, B. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60240-2 · Cited by 6,972
Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes
Nissen, S. E., & Wolski, K. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa072761 · Cited by 4,675 · cited 2×
“[9–11] The extent of therapeutic competition remains unknown but may be widespread given the frequency of multimorbidity in older adults and the emphasis of disease guidelines on prescribing one or more medications for treatment of chronic conditions.”
BackgroundClinician’s Guide to Prevention and Treatment of Osteoporosis
Cosman, F., de Beur, S. J., LeBoff, M. S., Lewiecki, E. M., Tanner, B., Randall, S., & Lindsay, R. (2014) · Osteoporosis International · doi:10.1007/s00198-014-2794-2 · Cited by 4,149
Nathan, D. M., Buse, J. B., Davidson, M. B., Ferrannini, E., Holman, R. R., Sherwin, R., & Zinman, B. (2009) · Diabetes Care · doi:10.2337/dc08-9025 · Cited by 3,834
Aging with multimorbidity: A systematic review of the literature
Marengoni, A., Angleman, S., Melis, R., Mangialasche, F., Karp, A., Garmen, A., Meinow, B., & Fratiglioni, L. (2011) · Ageing Research Reviews · doi:10.1016/j.arr.2011.03.003 · Cited by 3,092
Boyd, C. M., Darer, J., Boult, C., Fried, L. P., Boult, L., & Wu, A. W. (2005) · JAMA · doi:10.1001/jama.294.6.716 · Cited by 2,581 · cited 1×
“[2–8] Older adults with multi-morbidity are prescribed multiple medications for their individual conditions.”
BackgroundThe American Geriatrics Society 2012 Beers Criteria Update Expert Panel (2012) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.2012.03923.x · Cited by 2,578
Smith, S. C., Benjamin, E. J., Bonow, R. O., Braun, L. T., Creager, M. A., Franklin, B. A., Gibbons, R. J., Grundy, S. M., Hiratzka, L. F., Jones, D. W., et al. (2011) · Circulation · doi:10.1161/cir.0b013e318235eb4d · Cited by 1,759
Garber, J. R., Cobin, R. H., Gharib, H., Hennessey, J. V., Klein, I., Mechanick, J. I., Pessah-Pollack, R., Singer, P. A., & Woeber, K. A. (2012) · Endocrine Practice · doi:10.4158/ep12280.gl · Cited by 1,567 · cited 1×
“[16–29] When the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) system was used, all medication classes with an A (strong evidence) or B (moderate) grade were recorded.”
MethodUpdated Guidelines for the Diagnosis and Treatment of Gastroesophageal Reflux Disease
DeVault, K. R., & Castell, D. O. (2005) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2005.41217.x · Cited by 1,130
Garber, J. R., Cobin, R. H., Gharib, H., Hennessey, J. V., Klein, I., Mechanick, J. I., Pessah-Pollack, R., Singer, P. A., & Woeber for the American Association, K. A. (2012) · Thyroid · doi:10.1089/thy.2012.0205 · Cited by 1,053
Multimorbidity and quality of life in primary care: a systematic review
Fortin, M., Lapointe, L., Hudon, C., Vanasse, A., Ntetu, A. L., & Maltais, D. (2004) · Health and Quality of Life Outcomes · doi:10.1186/1477-7525-2-51 · Cited by 963
Adapting clinical guidelines to take account of multimorbidity
Guthrie, B., Payne, K., Alderson, P., McMurdo, M. E. T., & Mercer, S. W. (2012) · BMJ · doi:10.1136/bmj.e6341 · Cited by 530
Hallas, J., Dall, M., Andries, A., Andersen, B. S., Aalykke, C., Hansen, J. M., Andersen, M., & Lassen, A. T. (2006) · BMJ · doi:10.1136/bmj.38947.697558.ae · Cited by 403 · cited 1×
“Clopidogrel [42,43]”
Cohen, H. W., Gibson, G., & Alderman, M. H. (2000) · The American Journal of Medicine · doi:10.1016/s0002-9343(99)00301-0 · Cited by 390
Cited by
Fabbri, E., Zoli, M., Gonzalez-Freire, M., Salive, M. E., Studenski, S. A., & Ferrucci, L. (2015) · Journal of the American Medical Directors Association · doi:10.1016/j.jamda.2015.03.013 · Cited by 563
Multimorbidity in Older Adults With Cardiovascular Disease
Forman, D. E., Maurer, M. S., Boyd, C., Brindis, R., Salive, M. E., Horne, F. M., Bell, S. P., Fulmer, T., Reuben, D. B., Zieman, S., et al. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.03.022 · Cited by 484
“6% of older adults with multimorbidity (and with CVDs as the most common conditions that competed with others) (28).”
BackgroundDumbreck, S., Flynn, A., Nairn, M., Wilson, M., Treweek, S., Mercer, S. W., Alderson, P., Thompson, A., Payne, K., & Guthrie, B. (2015) · BMJ · doi:10.1136/bmj.h949 · Cited by 339
Boyd, C., Smith, C. D., Masoudi, F. A., Blaum, C. S., Dodson, J. A., Green, A. R., Kelley, A., Matlock, D., Ouellet, J., Rich, M. W., et al. (2019) · Journal of the American Geriatrics Society · doi:10.1111/jgs.15809 · Cited by 313
Self-citationAssessing medication burden and polypharmacy: finding the perfect measure
Gnjidic, D., Tinetti, M., & Allore, H. G. (2017) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2017.1301206 · Cited by 54
“among individuals with multimorbidity, it has also been shown that one-fifth of older adults will receive one medication that will adversely affect coexisting condition [9].”
BackgroundSelf-citation
Metadata
- Authors
- Lorgunpai, S. J., Grammas, M., Lee, D. S. H., McAvay, G., Charpentier, P., & Tinetti, M. E.
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2014-02-25
- Volume
- 9
- Issue
- 2
- Pages
- e89447
- ISSN
- 1932-6203 (ISSN-L)
- OpenAlex
- W1999194401
- Cited by
- 96
- References
- 15
- FWCI
- 4.80
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.